Business Wire

Ant International President Highlights AI and Connectivity as Key SME Growth Drivers

Share

Artificial Intelligence (AI) is being converted into flexible cross-border payment and digitisation solutions to help SMEs raise efficiency, lowering costs and controlling risks.More industry collaborations are needed to bridge payment systems and tech know-how.

Digital payment innovations are increasingly powerful tools for global businesses to raise productivity and turbocharge growth. The Digital Payment Market size1 is expected to grow at a CAGR of 11.8% and reach US$193.7 billion. However, there are digital divides and silos abound in core financial services for the global commerce system, especially in cross-border online and offline digital payment and settlement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312187829/en/

Douglas Feagin (left), President of Ant International, discussed payments innovation at GFTN Forum Japan in March 2025. (Photo: Business Wire)

“Even as technology advances in leaps and bounds, small businesses continue to face challenges in today’s digitised international transactions, from cross-border payment to cross-market growth,” said Douglas Feagin, President of Ant International, during the GFTN Forum held during the Japan Fintech Festival in Japan in March 2025. “We need to convert exciting developments in foundational technologies, such as AI, into comprehensive, effective and affordable solutions for the world’s long-tail business community.”

Ant International’s flagship Alipay+ cross-border mobile payment and digitisation technology has expanded to support 36 international payment apps, connecting over 90 million merchants across 66 markets. This “invisible” technology behind the cash register enables merchants to receive cross-border payments seamlessly and securely from individuals using their home e-wallets while maintaining competitive foreign exchange rates.

Interoperability is key, as local SMEs should be able to accept international payments more easily. In Asia, initiatives like national QRs have greatly boosted connectivity, and Alipay+ helps to bridge these infrastructures with our global payment partner users, but more needs to be done to bring together card and wallet-based ecosystems, Feagin said.

For SMEs, the capacity to accept various forms of international payments is not merely an advantage; it has become an essential factor for survival and growth in an increasingly competitive marketplace, Feagin noted.

Artificial Intelligence (AI) technology is crucial in addressing these pressing needs by providing tools that help SMEs make informed decisions swiftly, ensuring they meet customer demands while minimizing operational risks. A recent McKinsey report2 for 2025 underscores this importance, indicating that 92% of businesses plan to increase their AI investments this year. The consulting firm earlier predicted that companies integrating AI into their financial operations can expect productivity increases of up to 25%3.

At Ant International, AI-powered solutions are being developed to forecast currency demands based on transaction flows, enhancing efficiency in foreign exchange processes and steering the industry towards real-time payment systems.

For instance, Ant International’s AI-driven solution can forecast customers’ foreign-exchange needs with more than 90% accuracy based on provided data, which enables the company to help customers optimise their FX strategies.

As financial fraud becomes increasingly sophisticated, AI is paramount in safeguarding transactions. Ant International’s AI-powered risk management capabilities can effectively implement advanced fraud detection mechanisms that analyse patterns, identify anomalies, and protect against potential threats.

Interoperability will continue to be enhanced, particularly in Asia, where national QR systems and mobile wallets facilitate seamless transactions. This trend is expected to evolve rapidly as new LLM models are developed, enabling companies to streamline these workflows, said Feagin.

“We expect this revolution to continue at a rapid pace, and AI to accelerate efficiency and provide solutions for our customers,” added Feagin.

1https://www.marketsandmarkets.com/Market-Reports/digital-payment-market-209834053.html
2https://www.mckinsey.com/capabilities/mckinsey-digital/our-insights/superagency-in-the-workplace-empowering-people-to-unlock-ais-full-potential-at-work
3https://psico-smart.com/en/blogs/blog-how-can-artificial-intelligence-enhance-productivity-management-in-the-workplace-88579

View source version on businesswire.com: https://www.businesswire.com/news/home/20250312187829/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye